SpinalCyte announced the first injection in a clinical trial of CybroCell fibroblasts for spinal disc regeneration. The procedure was completed in under 15 minutes using a local anesthetic, and the patient was discharged within an hour.
SpinalCyte received Institutional Review Board approval to commence the randomized, placebo-controlled, double-blind Phase I clinical trial with CybroCell dermal fibroblast cell product in late 4Q16.
Sources: SpinalCyte, LLC; ORTHOWORLD Inc.
SpinalCyte announced the first injection in a clinical trial of CybroCell fibroblasts for spinal disc regeneration. The procedure was completed in under 15 minutes using a local anesthetic, and the patient was discharged within an hour.
SpinalCyte received Institutional Review Board approval to commence the randomized,...
SpinalCyte announced the first injection in a clinical trial of CybroCell fibroblasts for spinal disc regeneration. The procedure was completed in under 15 minutes using a local anesthetic, and the patient was discharged within an hour.
SpinalCyte received Institutional Review Board approval to commence the randomized, placebo-controlled, double-blind Phase I clinical trial with CybroCell dermal fibroblast cell product in late 4Q16.
Sources: SpinalCyte, LLC; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





